Lindsay Tara Fourman, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Growth Hormone-Releasing Hormone | 7 | 2024 | 128 | 3.100 |
Why?
|
HIV Infections | 22 | 2024 | 17275 | 1.710 |
Why?
|
Lipodystrophy | 2 | 2024 | 148 | 1.600 |
Why?
|
Hypertriglyceridemia | 1 | 2022 | 293 | 0.650 |
Why?
|
Growth Substances | 1 | 2021 | 768 | 0.640 |
Why?
|
Adiposity | 2 | 2019 | 1858 | 0.610 |
Why?
|
Drug Resistance | 1 | 2024 | 1593 | 0.600 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2024 | 2125 | 0.600 |
Why?
|
Insulin-Like Growth Factor I | 4 | 2021 | 1927 | 0.590 |
Why?
|
Absorptiometry, Photon | 2 | 2024 | 1735 | 0.570 |
Why?
|
Intra-Abdominal Fat | 2 | 2019 | 608 | 0.550 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2018 | 282 | 0.550 |
Why?
|
Placebos | 4 | 2024 | 1661 | 0.550 |
Why?
|
Aspartate Aminotransferases | 1 | 2017 | 415 | 0.530 |
Why?
|
Blood Proteins | 1 | 2021 | 1173 | 0.520 |
Why?
|
Hyperglycemia | 1 | 2024 | 1368 | 0.500 |
Why?
|
Macrophage Activation | 1 | 2018 | 552 | 0.490 |
Why?
|
Alanine Transaminase | 1 | 2017 | 604 | 0.490 |
Why?
|
Interleukin-10 | 1 | 2020 | 1174 | 0.470 |
Why?
|
Anti-Obesity Agents | 1 | 2017 | 227 | 0.460 |
Why?
|
Hypothalamic Diseases | 1 | 2015 | 134 | 0.450 |
Why?
|
Liver | 5 | 2023 | 7502 | 0.450 |
Why?
|
Receptor, Melatonin, MT1 | 1 | 2013 | 31 | 0.440 |
Why?
|
Neurosecretory Systems | 1 | 2015 | 221 | 0.440 |
Why?
|
Placenta | 2 | 2022 | 1702 | 0.430 |
Why?
|
Receptor, Melatonin, MT2 | 1 | 2013 | 81 | 0.420 |
Why?
|
Indenes | 1 | 2013 | 58 | 0.420 |
Why?
|
Fatty Liver | 1 | 2017 | 777 | 0.380 |
Why?
|
Hypoglycemic Agents | 1 | 2024 | 3069 | 0.380 |
Why?
|
Amenorrhea | 1 | 2015 | 480 | 0.370 |
Why?
|
Proteomics | 2 | 2023 | 3816 | 0.370 |
Why?
|
Hepatitis, Autoimmune | 1 | 2013 | 172 | 0.370 |
Why?
|
Monocytes | 3 | 2022 | 2570 | 0.370 |
Why?
|
Insulin | 1 | 2024 | 6578 | 0.330 |
Why?
|
Heart | 3 | 2022 | 4382 | 0.320 |
Why?
|
Receptors, Cell Surface | 1 | 2018 | 2825 | 0.310 |
Why?
|
Obesity | 3 | 2022 | 12870 | 0.310 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 2 | 2021 | 3217 | 0.310 |
Why?
|
Insulin Resistance | 1 | 2022 | 3941 | 0.300 |
Why?
|
Gene Expression | 1 | 2020 | 7583 | 0.290 |
Why?
|
Antigens, CD | 1 | 2018 | 3997 | 0.290 |
Why?
|
Liver Cirrhosis | 3 | 2023 | 1930 | 0.280 |
Why?
|
HIV | 3 | 2023 | 1581 | 0.270 |
Why?
|
Infertility | 2 | 2023 | 655 | 0.230 |
Why?
|
Hyperthyroidism | 2 | 2023 | 291 | 0.230 |
Why?
|
HIV-1 | 2 | 2020 | 6850 | 0.220 |
Why?
|
Coronary Artery Disease | 2 | 2020 | 6363 | 0.210 |
Why?
|
Pituitary Diseases | 1 | 2023 | 135 | 0.210 |
Why?
|
Double-Blind Method | 5 | 2024 | 12262 | 0.210 |
Why?
|
Cardiovascular Diseases | 3 | 2023 | 15396 | 0.210 |
Why?
|
Female | 28 | 2024 | 390316 | 0.210 |
Why?
|
Middle Aged | 19 | 2024 | 219560 | 0.200 |
Why?
|
HIV Integrase Inhibitors | 1 | 2024 | 165 | 0.200 |
Why?
|
Humans | 35 | 2024 | 758381 | 0.190 |
Why?
|
Growth Hormone | 2 | 2020 | 568 | 0.190 |
Why?
|
Matrix Metalloproteinase 2 | 1 | 2023 | 461 | 0.180 |
Why?
|
Infertility, Male | 1 | 2023 | 396 | 0.180 |
Why?
|
Dwarfism, Pituitary | 1 | 2020 | 39 | 0.180 |
Why?
|
Immunity | 2 | 2023 | 998 | 0.170 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2024 | 12076 | 0.170 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2021 | 206 | 0.170 |
Why?
|
Thyrotropin | 2 | 2023 | 832 | 0.160 |
Why?
|
Adult | 17 | 2024 | 219916 | 0.160 |
Why?
|
Hepatitis | 1 | 2020 | 229 | 0.160 |
Why?
|
Asymptomatic Diseases | 2 | 2018 | 584 | 0.150 |
Why?
|
Oxidative Phosphorylation | 1 | 2020 | 495 | 0.150 |
Why?
|
Pregnancy | 5 | 2024 | 29742 | 0.150 |
Why?
|
Blood Glucose | 2 | 2024 | 6347 | 0.150 |
Why?
|
Syndrome | 1 | 2024 | 3262 | 0.150 |
Why?
|
Male | 19 | 2024 | 358742 | 0.150 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2021 | 607 | 0.150 |
Why?
|
Thyroid Function Tests | 1 | 2018 | 289 | 0.140 |
Why?
|
T-Lymphocyte Subsets | 1 | 2024 | 1807 | 0.130 |
Why?
|
Longitudinal Studies | 2 | 2023 | 14481 | 0.130 |
Why?
|
Hormones | 1 | 2019 | 869 | 0.130 |
Why?
|
Young Adult | 7 | 2021 | 58808 | 0.130 |
Why?
|
Body Mass Index | 3 | 2024 | 12876 | 0.130 |
Why?
|
Human Growth Hormone | 1 | 2020 | 638 | 0.130 |
Why?
|
Tomography, X-Ray Computed | 1 | 2019 | 20500 | 0.130 |
Why?
|
Birth Weight | 1 | 2023 | 2097 | 0.120 |
Why?
|
Waist Circumference | 1 | 2019 | 922 | 0.120 |
Why?
|
Sex Factors | 2 | 2019 | 10505 | 0.120 |
Why?
|
Leptin | 1 | 2022 | 1591 | 0.110 |
Why?
|
Hyperprolactinemia | 1 | 2015 | 123 | 0.110 |
Why?
|
Up-Regulation | 1 | 2023 | 4114 | 0.110 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 851 | 0.110 |
Why?
|
Disease Management | 1 | 2024 | 2500 | 0.110 |
Why?
|
Weight Gain | 1 | 2023 | 2346 | 0.110 |
Why?
|
Adolescent | 6 | 2021 | 87888 | 0.110 |
Why?
|
Triglycerides | 1 | 2019 | 2450 | 0.100 |
Why?
|
Liver Function Tests | 1 | 2013 | 523 | 0.100 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2022 | 2115 | 0.100 |
Why?
|
Pituitary-Adrenal System | 1 | 2015 | 552 | 0.100 |
Why?
|
RNA, Viral | 1 | 2020 | 2836 | 0.100 |
Why?
|
Spleen | 1 | 2017 | 2296 | 0.090 |
Why?
|
Prenatal Exposure Delayed Effects | 1 | 2024 | 2496 | 0.090 |
Why?
|
Peritonitis | 1 | 2013 | 369 | 0.090 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2015 | 700 | 0.090 |
Why?
|
Adipose Tissue | 1 | 2022 | 3299 | 0.090 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2021 | 3480 | 0.090 |
Why?
|
Heart Failure | 3 | 2022 | 11594 | 0.090 |
Why?
|
Hypothyroidism | 1 | 2015 | 665 | 0.090 |
Why?
|
Body Composition | 1 | 2019 | 2416 | 0.080 |
Why?
|
Macrophages | 1 | 2024 | 5737 | 0.080 |
Why?
|
Cohort Studies | 3 | 2021 | 41252 | 0.080 |
Why?
|
Biopsy | 1 | 2021 | 6768 | 0.080 |
Why?
|
Viral Load | 1 | 2018 | 3321 | 0.080 |
Why?
|
Prednisone | 1 | 2013 | 1565 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1829 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2018 | 1780 | 0.080 |
Why?
|
Plaque, Atherosclerotic | 1 | 2020 | 1505 | 0.080 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2020 | 2292 | 0.070 |
Why?
|
Cardiomyopathies | 1 | 2019 | 1944 | 0.070 |
Why?
|
Treatment Outcome | 4 | 2024 | 64379 | 0.070 |
Why?
|
Myocardium | 1 | 2019 | 4690 | 0.070 |
Why?
|
Infant, Newborn | 2 | 2024 | 26182 | 0.070 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4313 | 0.070 |
Why?
|
Pituitary Neoplasms | 1 | 2015 | 1313 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2019 | 22031 | 0.070 |
Why?
|
Prevalence | 2 | 2020 | 15646 | 0.060 |
Why?
|
Infant | 2 | 2024 | 36054 | 0.060 |
Why?
|
Aged | 6 | 2021 | 168217 | 0.060 |
Why?
|
Disease Progression | 1 | 2021 | 13468 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10146 | 0.060 |
Why?
|
Adenoma | 1 | 2015 | 2148 | 0.060 |
Why?
|
Anti-HIV Agents | 1 | 2020 | 4504 | 0.060 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2013 | 1079 | 0.060 |
Why?
|
Liver Diseases | 1 | 2012 | 1296 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2013 | 1793 | 0.060 |
Why?
|
Databases, Factual | 1 | 2018 | 7980 | 0.050 |
Why?
|
Kidney Failure, Chronic | 1 | 2015 | 2457 | 0.050 |
Why?
|
Osteopontin | 1 | 2022 | 301 | 0.050 |
Why?
|
Risk Factors | 4 | 2020 | 73806 | 0.040 |
Why?
|
Ultrasonography | 1 | 2013 | 5952 | 0.040 |
Why?
|
Inflammation | 1 | 2020 | 10719 | 0.040 |
Why?
|
Thyroxine | 1 | 2023 | 667 | 0.040 |
Why?
|
Prognosis | 1 | 2020 | 29558 | 0.040 |
Why?
|
Child | 3 | 2023 | 79813 | 0.040 |
Why?
|
Receptors, Chemokine | 1 | 2022 | 655 | 0.040 |
Why?
|
Arteries | 1 | 2024 | 1125 | 0.040 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 36285 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2022 | 3858 | 0.040 |
Why?
|
United States | 3 | 2020 | 72140 | 0.040 |
Why?
|
Metabolic Diseases | 1 | 2024 | 682 | 0.040 |
Why?
|
Fibrosis | 1 | 2022 | 2038 | 0.030 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2022 | 1348 | 0.030 |
Why?
|
Prospective Studies | 4 | 2023 | 54136 | 0.030 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2021 | 1153 | 0.030 |
Why?
|
Focal Nodular Hyperplasia | 1 | 2012 | 29 | 0.030 |
Why?
|
Adenoma, Liver Cell | 1 | 2012 | 32 | 0.030 |
Why?
|
Child Development | 1 | 2024 | 2285 | 0.030 |
Why?
|
Massachusetts | 1 | 2024 | 8823 | 0.020 |
Why?
|
Reference Values | 1 | 2018 | 4919 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2019 | 3758 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2022 | 25953 | 0.020 |
Why?
|
Stroke Volume | 1 | 2022 | 5460 | 0.020 |
Why?
|
Hemangioma | 1 | 2012 | 727 | 0.020 |
Why?
|
Pilot Projects | 1 | 2020 | 8554 | 0.020 |
Why?
|
Cysts | 1 | 2012 | 681 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1190 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39060 | 0.020 |
Why?
|
Retrospective Studies | 2 | 2024 | 80170 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2021 | 15785 | 0.010 |
Why?
|
Algorithms | 1 | 2012 | 13959 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58681 | 0.000 |
Why?
|